/
/
/

Genpharmasec Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---11%
---827%
--24%-17%-36%
3%3%3%2%

Peer Comparison

Symbol
ADANIENT-A
PREMIERENE-A
CPPLUS-A
AEGISLOG-A
REDINGTON-A
HONASA-A
LLOYDSENT-A
CELLO-A
JSLL-A
BLACKROSE-T
GENPHARMA-X
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
2,886₹391876 Cr52.64-8.91105.06₹9339 Cr
1,002₹45373 Cr27.2510.245.28₹1510 Cr
3,726.35₹43958 Cr92.112.0745.29₹368 Cr
1,277.15₹43622 Cr34.8613.841.65₹898 Cr
374₹28378 Cr16.686.2224.36₹1490 Cr
475₹15338 Cr61.632.778.99₹200 Cr
71.62₹10831 Cr96.450.380.91₹283 Cr
343.5₹7658 Cr24.483.3217.83₹332 Cr
502.05₹6383 Cr26.985.2923.32₹222 Cr
112₹579 Cr20.222.046.4₹22 Cr
1.24₹69 Cr00.04₹56 L

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Mar 2023
₹50 Cr₹55 Cr₹40 Cr₹33 Cr₹12 Cr₹14 Cr₹8 Cr₹6 Cr₹5 Cr₹10 Cr₹6 Cr₹8 Cr₹6 Cr
₹37 L₹1 Cr₹98 L₹47 L₹70 L₹94 L₹81 L₹75 L₹57 L₹31 L₹14 L₹15 L₹6 L
₹50 Cr₹56 Cr₹41 Cr₹33 Cr₹13 Cr₹15 Cr₹9 Cr₹7 Cr₹6 Cr₹11 Cr₹7 Cr₹8 Cr₹6 Cr
₹49 Cr₹54 Cr₹42 Cr₹34 Cr₹11 Cr₹15 Cr₹8 Cr₹6 Cr₹5 Cr₹10 Cr₹6 Cr₹8 Cr₹6 Cr
₹1 Cr₹3 Cr-₹26 L-₹80,000₹2 Cr-₹8 L₹2 Cr₹87 L₹75 L₹30 L₹16 L₹11 L₹27 L
₹40 L₹48 L₹41 L₹23 L₹12 L₹11 L₹16 L₹7 L₹10 L₹16 L₹50,000₹7 L₹6 L
₹26 L₹2 Cr-₹1 Cr-₹80 L₹1 Cr-₹44 L₹1 Cr₹50 L₹49 L₹11 L₹3 L₹4 L₹20 L
-₹17 L₹1 Cr-₹83 L-₹1 Cr₹1 Cr-₹28 L₹76 L₹70 L₹29 L₹49 L₹6 L₹60,000₹1 Cr

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2025Mar 2024Mar 2023
₹55 Cr₹55 Cr₹28 Cr
₹10 Cr₹9 Cr-₹12 Cr
₹10 Cr₹9 Cr-₹12 Cr
₹65 Cr₹64 Cr₹15 Cr
₹12 L₹14 L₹0
₹3 Cr₹3 Cr₹2 Cr
-₹46 L-₹43 L-₹85 L
₹2 Cr₹68 L₹0
₹1 L₹0₹0
₹4 Cr₹3 Cr₹2 Cr
₹8 Cr₹2 Cr₹1 Cr
₹1 Cr₹32 L₹9 L
₹0₹0₹60 L
₹56 L₹0₹0
₹10 Cr₹3 Cr₹2 Cr
₹79 Cr₹71 Cr₹19 Cr
₹2 L₹2 L₹2 L
₹3 Cr₹3 Cr₹3 Cr
₹8 Cr₹93 L₹15 L
₹89 L₹10 L₹5 L
₹8 Cr₹84 L₹10 L
₹19 Cr₹18 Cr₹0
₹19 Cr₹18 Cr₹0
₹24 Cr₹11 Cr₹0
₹2 Cr₹0₹0
₹52 Cr₹30 Cr₹10 L
₹0₹2 Cr₹95 L
₹8 Cr₹9 Cr₹10 Cr
₹14 Cr₹9 Cr₹6 Cr
₹5 Cr₹19 Cr₹2 Cr
₹4 L₹38 L₹2 L
₹21 L₹2 Cr₹58 L
₹27 Cr₹41 Cr₹19 Cr
₹17 Cr₹38 Cr₹17 Cr
₹79 Cr₹71 Cr₹19 Cr
₹1₹1₹1
₹1₹1₹0

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2025Mar 2024Mar 2023
₹2 Cr₹25 L₹28 L
-₹1 Cr₹39 L₹16 L
₹2 Cr-₹4 Cr-₹4 Cr
₹3 Cr-₹3 Cr-₹3 Cr
₹3 Cr-₹3 Cr-₹3 Cr
-₹15 Cr-₹28 Cr₹36 L
-₹1 Cr₹48 Cr₹3 Cr
-₹14 Cr₹17 Cr₹39 L
₹19 Cr₹2 Cr₹2 Cr
₹5 Cr₹19 Cr₹2 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)1.26
Volume (₹)7.10 L
High (₹)1.33
Upper Circuit1.48
Low (₹)1.26
Lower Circuit1.00
Prev Close1.24
52W High (₹)2.15
Price1.26
52W Low (₹)0.75

Share Market Cap & Key Ratios Overview

M.Cap (₹)68.66 Cr
Div. Yield (%)0.00
PE Ratio0.00
Debt to Equity0.05
Price to Book1.61
Book Value1.18
EPS (TTM)-0.00
Face Value1.00
ROE (%)1.90

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
ADANIENT-ANSE
PREMIERENE-ANSE
AEGISLOG-ANSE
CPPLUS-ANSE
REDINGTON-ANSE
HONASA-ANSE
LLOYDSENT-ANSE
CELLO-ANSE
JSLL-ANSE
BLACKROSE-TNSE
GENPHARMA-XNSE
LTP
1W Low
1W High
Market cap (₹)
2935-231 (-7.30%)
2831.65
3168
3,90,684Cr
1002.35-11.65 (-1.15%)
995.50
1028.55
45,486Cr
1277.2-12.4 (-0.96%)
1180.45
1327.30
45,144Cr
3758.3+181.35 (5.07%)
3458.85
3796.35
44,346Cr
368.9+3.05 (0.83%)
343.80
378.95
29,113Cr
480.9+10.15 (2.16%)
465.25
494
15,566Cr
73.29+0.15 (0.21%)
69.53
74.50
10,984Cr
343.9-7.1 (-2.02%)
340.85
357.45
7,747Cr
509-2.95 (-0.58%)
497.75
529.70
6,238Cr
112.75-2.25 (-1.96%)
110.60
116.95
572Cr
1.26+0.23 (22.33%)
1.02
1.36
69Cr

Genpharmasec Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹1.33Cr; with other income of ₹37.3Lakh, profit before interest and tax came to ₹65.7Lakh. Interest expense was ₹39.9Lakh; PBT before exceptional items stood at ₹25.8Lakh. Cost mix (full year): raw materials ₹28.94Cr; employee cost ₹98.87Lakh; depreciation ₹67.4Lakh; other expenses ₹48.75Cr. Basis: consolidated annual results.

Genpharmasec Ltd Quaterly Results Key Takeaways

Genpharmasec Ltd reported ₹49.71Cr total income from operations in Jun 2026, softer than ₹55.43Cr in Mar 2026 but higher than ₹12.04Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹1.33Cr; with other income of ₹37.3Lakh, profit before interest and tax came to ₹65.7Lakh. Interest expense was ₹39.9Lakh, taking profit before tax to ₹25.8Lakh. After tax of ₹43.1Lakh, profit after tax stood at ₹-₹17.3Lakh (vs ₹1.35Cr in Mar 2026 and ₹1.21Cr in Jun 2025).